Some cookies on this site are essential, and the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links.
We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we won't set these cookies but some nice features of the site may be unavailable.
ITM's Virtual Radiotheranostic Satellite Symposium “Novel Approaches to Optimizing Targeted Radionuclide Therapy in Neuroendocrine Neoplasms” during the Virtual ENETS Conference on March 11, 2020.
There has been extensive experience with Targeted Radionuclide Therapy for Neuroendocrine Tumors (NETs) over a number of years, culminating in the approval of c.a. 177Lu-DOTATATE for the second line treatment of G1 and G2 NETs.
The optimal positioning of Targeted Radionuclide Therapy in the treatment of NET patients is presently unclear. First-line treatment of patients with pancreatic and nonfunctioning NETs is currently being explored in the COMPETE study, which compares n.c.a. 177Lu-Edotreotide with Everolimus. In addition, the study is exploring a number of parameters aimed towards optimizing treatment for individual patients.
There is increasing evidence pointing to the potential benefits of moving Targeted Radionuclide Therapy earlier in the treatment algorithm to first-line therapy of G1 and G2 NETs. The importance of a personalized approach to Targeted Radionuclide Therapy to optimize both efficacy and safety is becoming increasingly apparent. As part of this, the potential of liquid transcriptomics to identify possible non-responders to Targeted Radionuclide Therapy and their response to therapy is an area of particular focus. Patients with G3 Neuroendocrine Carcinomas (NECs) are less responsive to Targeted Radionuclide Therapy than patients with NETs. Combination therapies of Targeted Radionuclide Therapy with DNA repair inhibitors are a novel approach of sensitizing NECs to Targeted Radionuclide Therapy.
These three therapeutic topics are of great importance in realizing the potential of Targeted Radionuclide Therapy in patients with Neuroendocrine Neoplasms. We look forward to you being able to join us in what we hope will be a constructive contribution towards the clinical management of these patients.
Chair: Professor Jonathan Strosberg
Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Professor Jonathan Strosberg, Mo tt Cancer Center and Research Institute, Tampa, FL, USA
Should Targeted Radionuclide Therapy be off ered early or late in disease?
Jaume Capdevila, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain (15 mins)
Predicting responses to Targeted Radionuclide Therapy with liquid transcriptomics analysis
Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA (15 mins)
Combination therapy with DNA repair enzyme inhibitors
Professor Wolfgang Weber, University Hospital rechts der Isar, Munich, Germany (15 mins)
Panel discussion and summary
If you have any queries, please do not hesitate to contact us at enets(at)itm.ag